Politician trade (House)

Eli Lilly (LLY)Rep. Michael Rulli (OH06) disclosed a sale $1K–$15K

Rep. Michael Rulli (OH06) disclosed a sale of Eli Lilly in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
37 days
Disclosure lag
Traded
Jul 1, 2026
Disclosed
Aug 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 2, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  2. Jan 2, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  3. Mar 27, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  4. Apr 2, 2026Congress · 1 personMembers of Congress: 2 purchases
  5. Apr 14, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  6. May 6, 2026Insider · 1 personInsiders: 2 sales (~$15.8M)
  7. May 15, 2026Federal contract · $52K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $52K obligated to date
  8. Jun 9, 2026FDAFDA drug approval: Ebglyss
  9. Jun 10, 2026Insider · Their largest sale since 2022Officer sold ~$2.88M of LLY shares in the open market
  10. Jun 10, 2026Congress · 1 personMembers of Congress: 2 purchases
  11. Jul 1, 2026 · this disclosureCongressDisclosed sale of LLY — reported range $1,001 - $15,000

What came next

  1. Jul 10, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  2. Jul 13, 2026FDAFDA drug approval: Verzenio
  3. Jul 14, 2026FDAFDA drug approval: Retevmo
  4. Jul 14, 2026FDAFDA drug approval: Retevmo
  5. Jul 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.6%
  6. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
  7. Aug 7, 2026InsiderOfficer sold ~$5.95M of LLY shares in the open market
  8. Aug 10, 2026Insider · Their largest sale since 2014Officer sold ~$2.37M of LLY shares in the open market
  9. Aug 17, 2026Federal contract · $5K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $4.5K obligated to date
  10. Aug 17, 2026Insider · Their largest sale since 2022Officer sold ~$7.64M of LLY shares in the open market
  11. Aug 26, 2026FDAFDA drug approval: Zepbound
  12. Aug 27, 2026FDAFDA drug approval: Mounjaro
  13. Aug 27, 2026FDAFDA drug approval: Mounjaro
  14. Sep 18, 2026FDAFDA drug approval: Inluriyo
  15. Sep 18, 2026FDAFDA drug approval: Verzenio
  16. Sep 23, 2026FDAFDA drug approval: Onswik
  17. Sep 25, 2026FDAFDA drug approval: Olumiant
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Rep. Michael Rulli (OH06)

The full history of Rep. Michael Rulli (OH06) is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data